Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2 V617F in granulocytes [4]

British Journal of Haematology

Volumn 130, Issue 5, 2005, Pages 797-799

  Lasho, Terra L ^a   Mesa, Ruben ^a   Gilliland, D Gary ^b   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clonality; Mutation analysis; Myeloproliferative disorder

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; JANUS KINASE 2; BIOLOGICAL MARKER; JAK2 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ALLELE; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL POPULATION; CELL PROLIFERATION; CHRONIC NEUTROPHILIC LEUKEMIA; GENE MUTATION; GRANULOCYTE; HOMOZYGOSITY; HUMAN; LETTER; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; T LYMPHOCYTE; THROMBOCYTHEMIA; B LYMPHOCYTE; ENZYMOLOGY; GENETICS; HOMOZYGOTE; NUCLEOTIDE SEQUENCE;

ANTIGENS, CD19; ANTIGENS, CD3; ANTIGENS, CD34; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA MUTATIONAL ANALYSIS; GRANULOCYTES; HOMOZYGOTE; HUMANS; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; T-LYMPHOCYTES;

EID: 27244432586     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05682.x     Document Type: Letter

References (4)

1. Baxter E.J. Scott L.M. Campbell P.J. East C. Fourouclas N. Swanton S. Vassiliou G.S. Bench A.J. Boyd E.M. Curtin N. Scott M.A. Erber W.N. Green A.R. ( 2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054 1061.
2. James C. Ugo V. Le Couedic J.P. Staerk J. Delhommeau F. Lacout C. Garcon L. Raslova H. Berger R. Bennaceur-Griscelli A. Villeval J.L. Constantinescu S.N. Casadevall N. Vainchenker W. ( 2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature, in press Skoda R.C. ( 2005) A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. New England Journal of Medicine, 352, 1779 1790.
3. Reeder T.L. Bailey R.J. Dewald G.W. Tefferi A. ( 2003) Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood, 101, 1981 1983.
4. Steensma D.P. Dewald G.W. Lasho T.L. Powell H.L. McClure R.F. Levine R.L. Gilliland D.G. Tefferi A. ( 2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and the myelodysplastic syndrome. Blood, Blood First Edition Paper, prepublished online April 28, 2005; DOI 10.1182/blood-2005-03-1183 Gilliland D.G. ( 2005) JAK2 V617F in myeloproliferative disorders is not just another kinase. Cell Cycle, in press.